N/A N=24 Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=492 Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Phase 2 N=91 Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumor (GIST)
Primary: Recurrence-free Survival up to 60 Months — 9; 7; 2; 82 participants with an event
Phase 3 N=476 (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
GIST
Primary: Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors…
Phase 2 N=47 Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Sarcoma · Gastrointestinal Stromal Tumors
Primary: 2-year Relapse Free Survival Rate — 93.6 percentage of participants
Phase 3 N=644 A Study of Nilotinib Versus Imatinib in GIST Patients
Gastrointestinal Stromal Tumor (GIST)
Primary: Time to Progression Free Survival (PFS) — 25.9; 29.7 months — p=0.0081
Phase 2 N=6 A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
Primary: Estimated Steady-State Maximum Plasma Concentration (Cmax,ss) of Sunitinib and Its Metabolite — 37.98; 14.55 nanograms per milliliter (ng/mL)
Phase 3 N=361 A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Gastrointestinal Stromal Tumor
Primary: Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase — 27.3; 6.4 weeks — p=<0.001
Phase 2 N=27 A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumor
Primary: Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 — 18.5 percentage of participants
Phase 2 N=30 Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Phase 1 N=46 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Gastrointestinal Stromal Tumors (GIST) · Other Relapsed or Refractory Solid Tumors
Primary: Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib — 0; 0; 0; 0 patients with event(s) of dose-limiting
Phase 2 N=29 Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Advanced Gastrointestinal Stromal Tumors
Primary: Number of Participants With Non Progression at 4 Months — 3 Participants
Phase 2 N=16 BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Advanced Gastrointestinal Stromal Tumor (GIST)
Primary: Phase Ib Study: Number of Participants With Dose-Limiting Toxicities — 3; 8; 1; 3 Participants
Phase 2 N=39 A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumors
Primary: Progression-Free Survival (PFS) — 6.44 months
Phase 2 N=36 The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
Gastrointestinal Stromal Tumors · Soft Tissue Sarcomas
Primary: Change in Standardised Uptake Value (SUV)Max at Day 8, Central Review, (GIST) Gastrointestinal Stromal Tumours Patients. — -0.515 g/mL
N/A N=37 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2
Critical Illness · Oncology · Communication
Primary: Change in Prognostic Understanding — 0.58; 0.18 units on a scale
Phase 4 N=41 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Gastrointestinal Stromal Tumors
Primary: Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0. — 0; 14; 21; 6 Participants
Phase 2 N=34 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease…
Phase 2 N=148 A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Primary: Best Tumor Response (Core) — 0; 1; 49; 49 participants
N/A N=20 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1
Critical Illness · Oncology · Communication
Primary: Acceptability of the Proposed Intervention According to a Structured Qualitative Survey of Caregivers — 9; 10; 1; 3 Participants
Phase 2 N=20 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Carney Complex · Chondrosarcoma · Gastrointestinal Stromal Tumor
Primary: Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1 — 0 participants
Phase 2 N=36 A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumors
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 2 participants
Phase 3 N=81 Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival — 1.8; 0.9 Months
Phase 2 N=63 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
Phase 1 N=13 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Gastrointestinal Stromal Tumor
Primary: Number of Participants With Serious and Non-Serious Adverse Events — 4; 5; 4 Participants
Phase 2 N=108 A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Gastrointestinal Stromal Tumor(GIST)
Primary: Progression-free Survival (PFS) — 10.3; 8.3 months
Phase 2 N=25 Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Progression-free Survival (PFS) — 3.9 months
Phase 2 N=60 Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Clinical Benefit Response (CBR) According to RECIST — 15; 17; 32 participants
Phase 3 N=248 Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008) — 109.0; 111.0 days
Phase 3 N=199 Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival — 147; 28 Days — p=<0.000001